Agouron Pharmaceuticals
17
0
0
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
5.9%
1 terminated/withdrawn out of 17 trials
92.3%
+5.8% vs industry average
12%
2 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection
Role: collaborator
Effectiveness of Adding Interleukin-2 to Anti-HIV Drugs in Patients Recently Infected With HIV
Role: collaborator
A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments
Role: lead
A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3
Role: lead
A Study of Viracept in HIV-Positive Women
Role: lead
Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants
Role: lead
Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir
Role: lead
Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients
Role: lead
A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)
Role: lead
Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy
Role: lead
A Study on the Safety and Effectiveness of Twice-Daily Nelfinavir Plus Twice-Daily Indinavir Plus Efavirenz in HIV-Positive Patients Who Have Never Taken Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors
Role: collaborator
Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients
Role: lead
Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
Role: lead
A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis
Role: lead
Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)
Role: lead
Viracept Expanded Access Program
Role: lead
Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs
Role: lead
All 17 trials loaded